[1] Several monoclonal antibodies that bind to the CGRP receptor or peptide have been approved for prevention of migraine.
[2] Nerve activation triggers the release of CGRP and other neuropeptides, leading to inflammation, pain, and swelling.
[6] A study has found botox effective against necrotizing fasciitis caused by S. pyogenes in mice.
[25] As of February 2020, eptinezumab (Vyepti) was approved by the FDA for the treatment of migraine via intravenous infusion as well.
[26] Three small-molecule antagonists have been approved for treatment of migraine: ubrogepant, rimegepant, and atogepant.